Mesoblast (MESO) Assets Average (2015 - 2025)
Mesoblast (MESO) posted Assets Average of $783.5 million for Q4 2025, up 8.97% sequentially from $719.0 million in Q2 2025, and up 18.49% YoY from $661.2 million in Q4 2024.
Mesoblast (MESO) Assets Average (2015 - 2025) Analysis & Trends
Mesoblast has reported Assets Average for 10 years, with the latest figure at $783.5 million in Q4 2025.
- Quarterly Assets Average rose 18.49% year-over-year to $783.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $783.5 million (up 18.49% YoY) and the FY2025 annual result came in at $726.9 million, up 8.61% from the prior year.
- Assets Average climbed to $783.5 million in Q4 2025 per MESO's latest filing, from $719.0 million in the prior quarter.
- Over five years, Assets Average peaked at $783.5 million in Q4 2025 and troughed at $659.3 million in Q1 2023.
- A 5-year average of $697.7 million and a median of $676.3 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average decreased 11.05% in 2022, then rose 18.49% in 2025.
- Over 5 years, Assets Average stood at $713.1 million in 2021, then fell by 5.17% to $676.3 million in 2022, then fell by 0.95% to $669.8 million in 2023, then declined by 1.29% to $661.2 million in 2024, then grew by 18.49% to $783.5 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $783.5 million, $719.0 million, and $661.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | 783.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 783.50 Mn |
| Jun 30, 2025 | 719.00 Mn |
| Dec 31, 2024 | 661.24 Mn |
| Jun 30, 2024 | 669.72 Mn |
| Dec 31, 2023 | 669.85 Mn |
| Jun 30, 2023 | 659.93 Mn |
| Mar 31, 2023 | 659.25 Mn |
| Dec 31, 2022 | 676.28 Mn |
| Sep 30, 2022 | 673.32 Mn |
| Jun 30, 2022 | 671.92 Mn |
| Mar 31, 2022 | 693.06 Mn |
| Dec 31, 2021 | 713.13 Mn |
| Sep 30, 2021 | 733.27 Mn |
| Jun 30, 2021 | 755.42 Mn |
| Mar 31, 2021 | 726.72 Mn |
| Dec 31, 2020 | 699.94 Mn |
| Sep 30, 2020 | 723.09 Mn |
| Jun 30, 2020 | 699.70 Mn |
| Mar 31, 2020 | 678.01 Mn |
| Dec 31, 2019 | 672.01 Mn |